Aim: The potential of long noncoding RNA in hepatocellular carcinoma (HCC) has led to promising insights into therapeutic intervention. The clinical significance of LINC02518 in HCC is unclear. Thi...
Whether endobiliary radiofrequency ablation (EB-RFA) changes the standard role of stent placement in treating unresectable malignant biliary obstruction (MBO) remains unclear. The aim of this study is to compare percutaneous EB-RFA and metal stent placement (RFA-Stent) with metal stent placement alone (Stent) in treating unresectable MBO using a propensity score matching (PSM) analysis. From June 2013 to June 2018, clinical data from 163 patients with malignant biliary obstruction who underwent percutaneous RFA-Stent or stenting alone were retrospectively analyzed using a nearest-neighbor algorithm to one-to-one PSM analysis to compare primary and secondary stent patency (PSP, SSP), overall survival (OS) and complications between the two groups. Before matching, for whole patients, RFA-Stent resulted in longer median PSP (8.0 vs. 5.1 months, P = 0.003), SSP (9.8 vs. 5.1 months, P < 0.001) and OS (7.0 vs. 4.5 months, P = 0.034) than the Stent group. After matching (54 pairs), RFA-Stent also resulted in better median PSP (8.5 vs. 5.1 months, P < 0.001), SSP (11.0 vs. 6.0 months, P < 0.001), and OS (8.0 vs. 4.0 months, P = 0.007) than Stent. RFA-Stent was comparable with Stent for complication rates. In Cox analysis, RFA-Stent modality and serum total bilirubin level were independent prognostic factors for PSP. RFA-Stent modality, performance status score and combination therapy after stent were independent prognostic factors for OS. Percutaneous RFA-Stent was superior to Stent in terms of PSP, SSP, and OS in selected patients with unresectable MBO.
1 June 2025 in Quantitative Imaging in Medicine and Surgery
Background: Robotic technologies have promising applications in computed tomography (CT)-guided puncture. However, nodule-surrogate models can be difficult to develop for relevant studies, and thus the accuracy of optical navigation robot-assisted puncture remains unclear. This study aims to evaluate a starch mixture (the starch group) and a copper particle nodule-surrogate model (the particle group) and to compare the accuracy of optical navigation robot-assisted puncture (the robot group) with traditional CT-guided manual puncture (the manual group) using swine liver and kidneys. Methods: The study was approved by the institutional animal care and use committee. Ex vivo and in vivo studies of three swine liver and kidney samples using nodule surrogates were imaged by CT scan to assess the accuracy of the starch and particle groups. In an in vivo study of six swine, 24 punctures made by the robot and manual groups were performed using copper particle nodule-surrogate targets in the liver and kidneys under CT guidance. The accuracy of insertion was evaluated with a 5.0-mm margin. The needle insertion time, level of radiation exposure, and complications were evaluated. Results: In the first experiment, all nodule surrogates were easily visible on the CT images. However, other aspects of the starch group (one starch overflow, one starch dispersion event, and one air embolism) were inferior to those of the particle group. In experiment 2, the accuracy of needle insertion in the robot group (3.71±1.34 mm) was higher than in the manual group (11.89±9.59 mm) (P<0.001). The needle insertion time and level of radiation exposure were superior in the robot group compared to the manual group. Complications were similar between the two groups. Conclusions: The particle method may be superior to the starch method. The robot group was more accurate than the manual group, and the occurrence of complications was similar.
1 November 2026 in Quantitative Imaging in Medicine and Surgery
Drug-eluting bead bronchial artery chemoembolization (DEB-BACE) has been investigated as a locoregional salvage treatment for advanced non-small cell lung cancer (NSCLC). It may be considered for treatment-refractory or symptomatic central tumors. We retrospectively describe case of three patients with centrally located, treatment-refractory NSCLC who underwent DEB-BACE. All three subsequently expectorated soft-tissue material. Clinical features, procedures, imaging, pathology, and outcomes were reviewed. Potential bronchial and non-bronchial systemic tumor-feeding arteries were assessed using contrast-enhanced computed tomography and selective digital subtraction angiography (DSA). Lobaplatin was infused intra-arterially. Embolization was then performed with 300 to 500 μm epirubicin-loaded Bead microspheres. The procedural endpoint was marked reduction of tumor blush with stasis or near-stasis. One patient had SMARCA4-deficient NSCLC. Two had squamous cell carcinoma. Soft-tissue expectoration occurred 3 days to 2 weeks after DEB-BACE. Histopathology confirmed carcinoma with extensive necrosis in Cases 1 and 2. Pathological confirmation was unavailable in Case 3. Case 1 achieved a durable partial response during repeated DEB-BACE and continued sintilimab treatment. The tumor decreased from 94 mm × 55 mm to 22 mm × 14 mm at 13 months and remained stable at 29 months. Case 2 developed tumor expectoration 3 days after treatment. Bronchial patency was subsequently restored. The patient died 10 months after diagnosis. Case 3 developed recurrent hemoptysis and underwent emergency hemostatic bronchial artery embolization. The patient subsequently expectorated a soft-tissue mass and died from progressive pulmonary infection 14 months after diagnosis. Tumor expectoration may represent treatment-associated necrosis after DEB-BACE. Careful assessment of vascular anatomy, bleeding risk, infection, and non-target embolization risk is essential.
1 April 2025 in Quantitative Imaging in Medicine and Surgery
Background: The treatment strategy for previously standard treated non-small cell lung cancer (NSCLC) still remains challenged. This study was to evaluate the effectiveness and safety of epirubicin-loaded drug-eluting bead transbronchial artery chemoembolization (D-BACE) plus bronchial artery infusion chemotherapy (BAIC) in patients with refractory advanced NSCLC. Methods: Between January 2018 and December 2022, 32 patients with refractory advanced NSCLC [26 males; mean age of 64±9.3 (range, 41–78) years; 19 squamous carcinomas (59.4%)] who had received one or more previous standard treatments and received D-BACE (epirubicin 50 mg) plus BAIC (lobaplatin 30 mg/m2) were included in our study. The study evaluated several parameters including local tumor response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, progression-free survival (PFS), overall survival (OS), and complication rates. To examine the impact of different factors on PFS and OS, Kaplan-Meier and Cox regression analyses were performed. Results: A total of 68 D-BACE plus BAIC sessions (median, 1, range 1–7) were performed. Overall response and disease control rates were 25% and 100%, respectively. The median PFS and median OS were 6.0 months [95% confidence interval (CI): 4.1–7.9] and 14.0 months (95% CI: 4.8–23.2), respectively. The number of cycles in the D-BACE plus BAIC treatment was found to be an independent predictor of PFS and OS. There were no instances of severe procedure-related complications or deaths during the study. Conclusions: The combination of D-BACE and BAIC shows great potential as a treatment choice for patients with refractory advanced NSCLC.